Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack?

被引:64
作者
Bednarczuk, Tomasz
Gopinath, Bamini
Ploski, Rafal
Wall, Jack R.
机构
[1] Univ Sydney, Western Clin Sch, Nepean Hosp, Dept Med, Penrith, NSW 2751, Australia
[2] Med Univ Warsaw, Dept Endocrinol, Warsaw, Poland
[3] Polish Acad Sci, Dept Endocrinol, Med Res Ctr, Warsaw, Poland
[4] Med Univ Warsaw, Dept Med Genet, Warsaw, Poland
关键词
D O I
10.1111/j.1365-2265.2007.02854.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The variety of clinical presentations of eye changes in patients with Graves' disease suggests that complex interactions between genetic, environmental, endogenous and local factors influence the development/severity of Graves' ophthalmopathy (GO). At present, the role of genetic factors in the development of GO remains unknown. Based on small case-control association studies with candidate genes, several susceptibility loci in GO have been proposed. These are human leucocyte antigen (HLA, 6p21.3), cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33), tumour necrosis factor (TNF, 6p21.3), interferon-gamma (IFN-gamma, 12q14), intercellular adhesion molecule-1 (ICAM-1, 19p13), and thyroid stimulating hormone receptor gene (TSH-R, 14q31). Unfortunately, these results were either not confirmed or require replication in larger studies. There are many reasons for the lack of reproducibility of association studies in GO, including poor characterization of the studied groups and small sample sizes, which may result in both false positive and negative results. Thus, the genetic background of GO remains to be elucidated in future research. However, the possibility that GO may be a genetically heterogeneous disorder, or that the development of GO may be predominantly influenced by environmental factors such as cigarette smoking, can not be disregarded.
引用
收藏
页码:3 / 19
页数:17
相关论文
共 136 条
[1]   New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy [J].
Ajjan, RA ;
Weetman, AP .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (03) :237-245
[2]   MHC class II region, CTLA4 gene, and ophthalmopathy in patients with Graves' disease [J].
Allahabadia, A ;
Heward, JM ;
Nithiyananthan, R ;
Gibson, SM ;
Reuser, TTQ ;
Dodson, PM ;
Franklyn, JA ;
Gough, SCL .
LANCET, 2001, 358 (9286) :984-985
[3]   STATISTICS NOTES - ABSENCE OF EVIDENCE IS NOT EVIDENCE OF ABSENCE [J].
ALTMAN, DG ;
BLAND, JM .
BRITISH MEDICAL JOURNAL, 1995, 311 (7003) :485-485
[4]   Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy [J].
Aniszewski, JP ;
Valyasevi, RW ;
Bahn, RS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :776-780
[5]  
AREND WP, 1993, TXB RHEUMATOLOGY, V1, P227
[6]   Genetic markers in diagnosis and prediction of relapse in Graves' disease [J].
Badenhoop, K ;
Donner, H ;
Braun, J ;
Siegmund, T ;
Rau, H ;
Usadel, KH .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1996, 104 :98-100
[7]   TUMOR NECROSIS FACTOR-BETA GENE POLYMORPHISMS IN GRAVES-DISEASE [J].
BADENHOOP, K ;
SCHWARZ, G ;
SCHLEUSENER, H ;
WEETMAN, AP ;
RECKS, S ;
PETERS, H ;
BOTTAZZO, GF ;
USADEL, KH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 74 (02) :287-291
[8]   Fine-tuning of T lymphocytes in autoimmunity: genetic association of CTLA-4 variants and Graves' disease revisited [J].
Badenhoop, K ;
Seidl, C .
CLINICAL ENDOCRINOLOGY, 2003, 59 (05) :555-557
[9]   TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthalmopathy [J].
Bahn, RS .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2004, 27 (03) :216-220
[10]   Pathophysiology of Graves' ophthalmopathy: The cycle of disease [J].
Bahn, RS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (05) :1939-1946